Last mentioned: Mar 10, 2026
FY 2025 Earnings
Legend Biotech reports full-year financial results and 2026 strategic outlook.
Pipeline Update
Initial Phase 1 data released for solid tumor candidates in neuroendocrine carcinoma.
Manufacturing Milestone
Ghent facility reaches full operational capacity for commercial production.
Label Expansion
Carvykti receives FDA approval for earlier lines of multiple myeloma treatment.
Legend Biotech (LEGN) has released its full-year 2025 financial results, showcasing significant revenue growth driven by the continued commercial expansion of its lead CAR-T therapy, Carvykti. The company highlighted major manufacturing milestones and a strategic pivot toward solid tumor indications following a year of intensive market penetration in earlier lines of multiple myeloma treatment.
This page surfaces every story mentioning Legend Biotech across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Legend Biotech was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |